marijuana stocks news

Cara Therapeutics to Announce First Quarter 2015 Financial Results on May 12, 2015

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 12, 2015, at 4:30 p.m. ET to report first quarter 2015 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 41947428. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Contact:
Investor Contact
Jesse Baumgartner
Stern Investor Relations
212-362-1200
jesse@sternir.com
Media Contact
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

CBD Unlimited, Inc. (EDXC) Announces Fiscal Year-End Financial Results

CBD Unlimited Announces Fiscal Year-End Financial Results; Year-Over-Year Revenues Grow 88 Percent…

INSYS Therapeutics, Inc. (INSY) Completes Initial Clinical Study of Dronabinol Inhalation

INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated…

HEXO Corp (HEXO) Leadership Transition; Company Appoints Charlie Bowman as Chief Executive Officer

HEXO Announces Leadership Transition; Company Appoints Charlie Bowman as Chief Executive Officer…

Future Farm Technologies Inc. (FFRMF) Provides Update on its Cannabis Breeding, Biochemistry and In-vitro Propagation Business Segment

Future Farm Provides Update on its Cannabis Breeding, Biochemistry and In-vitro Propagation…